Sign in
Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma
Journal article   Open access  Peer reviewed

Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma

Dan T Vogl, David Dingli, Robert Frank Cornell, Carol Ann Huff, Sundar Jagannath, Divaya Bhutani, Jeffrey Zonder, Rachid Baz, Ajay Nooka, Joshua Richter, …
Journal of clinical oncology, Vol.36(9), pp.859-866
2018-03-20
PMCID: PMC6905485
PMID: 29381435

Abstract

Triazoles - administration & dosage Triazoles - adverse effects Dexamethasone - administration & dosage Administration, Oral Humans Middle Aged Antineoplastic Combined Chemotherapy Protocols - adverse effects Dexamethasone - adverse effects Male Multiple Myeloma - metabolism Dose-Response Relationship, Drug Multiple Myeloma - drug therapy Karyopherins - metabolism Antineoplastic Combined Chemotherapy Protocols - therapeutic use Active Transport, Cell Nucleus - drug effects Progression-Free Survival Receptors, Cytoplasmic and Nuclear - antagonists & inhibitors Adult Female Aged Hydrazines - administration & dosage Karyopherins - antagonists & inhibitors Hydrazines - adverse effects Receptors, Cytoplasmic and Nuclear - metabolism
url
https://doi.org/10.1200/JCO.2017.75.5207View
Published (Version of record) Open

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
Citation topics
1 Clinical & Life Sciences
1.130 Lymphomas
1.130.617 Multiple Myeloma
Web Of Science research areas
Oncology
ESI research areas
Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Details